Taken together, our data clearly demonstrate that PRDX1-mediated CUL5 neddylation and subsequent NOXA degradation must be one of the strategies by which CRC cells counteract the toxic effect of chemotherapeutics (Fig. 7H). This evidence concerns the gene CUL5 and colorectal carcinoma.